bluebird bio ‘baffled’ after NICE rejects beta-thalassaemia gene therapy – – pharmaphorum

Its back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its beta thalassaemia gene therapy Zynteglo for regular NHS use in first draft guidance. NICE is assessing Zynteglo (betibeglogene autotemcel), a one-off gene therapy for the condition, which can have life-threatening consequences and is associated with a curtailed life expectancy. There is a curative treatment for people who rely on blood transfusions to survive and maintain their levels of red blood cells

Read more
3D bioprinting paves way for functional adult-sized tissues and organs – News-Medical.Net

Research into 3D bioprinting has grown rapidly in recent years as scientists seek to re-create the structure and function of complex biological systems from human tissues to entire organs. The most popular 3D printing approach uses a solution of biological material or bioink that is loaded into a syringe pump extruder and deposited in a layer-by-layer fashion to build the 3D object.

Read more